The Chief Financial Officer of NervGen Pharma (NGENF) is Buying Shares
Today, the Chief Financial Officer of NervGen Pharma (NGENF), William James Adams, bought shares of NGENF for $60K.
This is Adams’ first transaction since reporting a Buy transaction on TSE:RBM back in December 2015 In addition to William James Adams, one other NGENF executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, NervGen Pharma has an average volume of 20.73K. The company has a one-year high of $2.49 and a one-year low of $0.55. The Company has a Price to Book ratio of 9.85.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NervGen Pharma Corp is a regenerative medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company’s lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.